The federal government has scheduled a hearing on whether recreational marijuana should move from Schedule I to Schedule III after taking a narrower action involving certain FDA-approved and state-licensed medical products.
Under the phased process, qualifying medical marijuana products reportedly received Schedule III treatment, while other marijuana remains in Schedule I. A medical marijuana patient should understand that this limited change is separate from the broader rulemaking. Because the next phase concerns marijuana more generally, its outcome could also affect businesses operating in state recreational or adult-use markets.
The DEA hearing begins June 29, 2026, and will consider evidence and expert testimony. It is not a separate recreational-marijuana proceeding, but the broader classification under review may affect both medical and recreational cannabis operations.
What Marijuana Rescheduling Action Has Already Taken Effect?
The action already taken applies to marijuana in FDA-approved products and marijuana regulated under qualifying state medical marijuana licenses.
This creates a narrower path for certain medical products without completing the proposed transfer of marijuana generally. Marijuana outside those categories remains subject to Schedule I treatment for now.
Businesses that participate in both medical and recreational markets may therefore face different federal treatment. Their qualifying medical activity may fall under the new approach, while recreational marijuana activity remains connected to Schedule I unless the broader rulemaking results in a wider Schedule III transfer.
What Could the Broader Hearing Mean for Recreational Marijuana?
The hearing could influence how federal scheduling rules apply to marijuana outside the qualifying medical categories, including products handled by state recreational businesses. No final decision has been made about that broader transfer.
The current process involves two developments: a narrower change for qualifying medical marijuana products and a hearing on whether marijuana generally should move from Schedule I to Schedule III.
President Trump’s December 2025 executive order stating cannabis is now Schedule III did not itself declare all cannabis to be Schedule III. It directed the attorney general to complete the pending rescheduling process as quickly as federal law permits.
For recreational businesses, the central question is whether the final action will extend Schedule III treatment beyond the medical products already covered. Until that happens, adult-use marijuana outside those categories remains in Schedule I.
What Will the June 2026 Hearing Consider?
The hearing will consider factual evidence and expert opinion about whether marijuana meets the requirements for placement in Schedule III.
The proposal reflects the view that marijuana has an accepted medical use, has less potential for abuse than substances in Schedules I and II, and may lead to moderate or low physical dependence or high psychological dependence.
Selected participants may present testimony and evidence. The proceeding will create an administrative record for consideration before a final decision is made, but it does not guarantee that marijuana will move to Schedule III.
Why Is the DEA Holding a New Hearing?
The DEA is holding a new hearing because the earlier proceeding ended before the broader rescheduling proposal was completed.
The original Schedule III proposal was published in May 2024. A hearing was later planned, but that process was withdrawn and terminated. The federal marijuana rescheduling announced by the Department of Justice reflects the renewed effort to move the unresolved proposal forward through a formal hearing.
A December 2025 executive order directed the attorney general to complete the process as quickly as federal law permits. Expedited does not mean automatic, because federal scheduling and rulemaking procedures still apply.
When Will the Marijuana Rescheduling Hearing Take Place?
The hearing is scheduled to begin on June 29, 2026.
The proceeding is expected to conclude no later than July 15. The administrative law judge may continue, move, or recess the hearing when necessary.
July 15 is the deadline for concluding the hearing, not a guaranteed final-decision date. The government will still need to review the record and decide how to proceed.
Would Schedule III Federally Legalize Recreational Marijuana?
Moving marijuana to Schedule III would not federally legalize recreational marijuana.
Schedule III substances remain controlled under federal law. Rescheduling would change marijuana’s classification and could reduce some Schedule I restrictions, but it would not remove marijuana from the Controlled Substances Act.
State recreational programs would not become federally legal simply because marijuana moved to Schedule III. Rescheduling, descheduling, and legalization are separate policy actions.
What Could Change for Recreational Businesses Under Schedule III?
Broader Schedule III treatment could affect federal taxation, research, and the treatment of mixed medical-and-recreational businesses.
Section 280E prevents businesses trafficking in Schedule I or II substances from deducting many ordinary business expenses. Companies serving both medical and recreational customers may initially receive relief only for qualifying medical operations. If the broader transfer is finalized, recreational operations could potentially gain access to deductions that remain unavailable while their marijuana activity is tied to Schedule I.
Moving marijuana to Schedule III could also reduce some research barriers and expand studies of medical use, product safety, dosing, and potential risks.
These changes could be financially significant for adult-use businesses, but they would not erase the distinction between state authorization and federal legalization.
What Has Not Yet Been Decided?
The broader transfer of marijuana from Schedule I to Schedule III has not been finalized.
The hearing has not begun, the evidence has not been presented, and the government has not announced a final outcome. It also remains uncertain exactly how a final Schedule III action would apply across medical-only, recreational-only, and mixed-market businesses.
What Should Patients Watch Next?
Patients should watch the hearing and any later federal decision.
June 29 is the scheduled start, and July 15 is the current deadline for its conclusion. Recreational businesses should watch whether the final action extends beyond qualifying medical products and how any new classification affects Section 280E treatment.
What Is the Bottom Line on Federal Marijuana Rescheduling?
The federal government has taken a limited step involving certain qualifying medical marijuana products while continuing to review the broader classification of marijuana.
The June 2026 hearing will examine whether marijuana should move from Schedule I to Schedule III. A broader transfer could affect recreational cannabis businesses through federal tax treatment and reduced research barriers, but it would not federally legalize adult-use marijuana.
For patients, providers, and cannabis businesses, the key is to separate what has already changed from what remains under consideration.
Get Medical Marijuana Support From DocMJ
At DocMJ, we connect patients with qualified medical marijuana doctors for evaluations, certifications, and renewals. We guide patients through state program requirements, required appointments, and the steps needed to maintain legal medical cannabis access. Book an appointment with us for professional support as federal marijuana policies continue to change nationwide.
Make Us Your Preferred Source
Enjoyed this blog? Use this link to make us your preferred source for the latest insights, tips, and updates: https://www.google.com/preferences/source?q=https://docmj.com/
Choosing us as a preferred source tells Google you would like to see more relevant content from DocMJ and makes helpful information from our team easier to find.
Aaron Bloom, an experienced healthcare attorney, serves as the CEO of DocMJ and Medwell Health and Wellness Centers, where he has overseen the organizations’ mission and growth since 2016. In addition to his leadership roles, Aaron serves on the Board of Directors for Waterfall Bank, bringing his expertise in healthcare, compliance, and strategic growth to the financial services sector.
Aaron’s passion for improving patients’ lives stems from more than 20 years of owning, operating, and representing traditional healthcare organizations. Throughout his career, he has remained committed to finding better ways to relieve suffering and expand access to innovative, patient-centered care. As CEO, Aaron works each day to help patients achieve better health and wellness through the therapeutic benefits of medical cannabis and other evidence-based alternative medicines.